home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  October 23, 2019
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 524 active entries

Seco-Steroidal Discovery

An SBO Company
Toll free: +011-604-941-9022

Phone: +011-604-945-8408
Fax: +011-604-941-9022


Our projects are exclusively our own proprietary property and meant for information purposes only. We began with our Principal Investigators work earlier in the 1980 with plant product Lanosterol at Simon Fraser University BC CANADA which led later to our work on drug therapy with VitD metabolism as it applies to chronic or acute inflammation and related occupational-related or life-style diseases such as diabetes type2, atherosclerosis or heart disease and certainly some if most cancers (e. g. breast and colon). 

[1] Seco-steroidal drugs to effect receptors on the cell membrane involved to therapeutically address cholesterol uptake at the gut level and metabolically, post-absorptively (readily on the market).

[2] Seco-steroidal drugs to effect antagonism of feed-back inhibition (FBI) VitD effector functions and prolong their active state as with our Retonobionols (R) to help control of prevent the prevalence of cancers and other chronic inflammatory disease conditions of the body.

[3] Steroidal analogues to compete with and control, via this pharma, the esterifications and storage of cholesterol in shell eggs with poultry. This proposal further expands on (see: [2] above) the theme of cholesterol whole-body metabolism and its emptying into the digestive tract through bile juice from the duct.

[4] Steroidal analogues in plant secoundary alkaloid derivatives that bind to mother cell mitotic spindle fibres and prevent pollination in genetically manipulated biosafe plant life.

Since 1992 until it closing in 1995 after achieving honours standing in lab bench research performance with his work from an NSERC/MRC Canadian grant and then an OPRS award from Australia, our Principal Investigator plans to continue publishing his own research results on seco-steroidal drug discovery. He currently is on partial foundational granting from the Canadian Academy of Independent Scholars, SFU.ca, Adult Continuing Education, downtown Vancouver, BC. 



Selected Categories:
Product Company   Service Company
- General
- Research
- Communications

Last update of this entry: May 19, 2019

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2019 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.